Biologics and small molecules for perianal Crohn’s disease: a systematic review and meta-analyses of randomized placebo-controlled trials
Abstract
Background: Although several advanced therapies (ATs) for luminal Crohn’s disease (CD) have been approved, their efficacy for perianal fistulizing Crohn’s (pCD) has not been comprehensively reviewed.
Methods: A literature search was conducted in MEDLINE, Embase, and Cochrane CENTRAL up to October 2, 2025. Placebo-controlled randomized controlled trials (RCTs) evaluating treatment efficacy in pCD were included. Outcomes of interest were fistula response and fistula remission during the induction and maintenance trials. Pooled relative risks (RRs) were calculated using a random-effects model.
Results: Fourteen studies were eligible; only 4 RCTs were specifically designed for pCD, while the remainder were post hoc analyses of luminal CD studies with moderate to serious risk of bias. In pooled analyses of induction trials (4-28 weeks), ATs were associated with significantly higher induction of fistula response (RR 1.65, 95% CI 1.22-2.22) and remission (RR 1.91, 95% CI 1.37-2.67) compared to placebo. Infliximab and upadacitinib demonstrated significantly greater fistula response and remission, while ustekinumab significantly increased rates of fistula remission. For the maintenance phase (22-52 weeks), ATs were associated with significantly higher maintenance of fistula response (RR 1.54, 95% CI 1.21-1.97) and remission (RR 2.08, 95% CI 1.49-2.90) compared to placebo. Infliximab showed significantly greater maintenance of fistula response and remission compared with placebo, while adalimumab was superior for fistula remission.
Conclusion: Findings from our meta-analysis indicate that infliximab is effective for pCD, with limited evidence of benefit with adalimumab, ustekinumab, and upadacitinib. Well-designed RCTs investigating newer advanced therapies are needed to better guide targeted treatment strategies for this patient population.
Related
- Can physical exercise improve allergic rhinitis symptoms in adults? A systematic review of randomized controlled trials
- Hemoadsorption to prevent acute kidney injury in elective cardiac surgery: a systematic review of randomized controlled trials with meta-analysis and trial sequential analysis
- Hydrolyzed Rice Formula for the Management of Cow’s Milk Allergy in Infants and Young Children: A Systematic Review of Randomized Controlled Trials
- Placebo-arm response rates for pain outcomes in chronic pancreatitis: a systematic review and meta-analysis of randomized controlled trials
- Dietary Polyphenols as Adjunctive Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
BibTeX
@article{yuan2026biologics,
title = {{Biologics and small molecules for perianal Crohn’s disease: a systematic review and meta-analyses of randomized placebo-controlled trials}},
author = {Yuhong Yuan and Vipul Jairath and Jurij Hanzel and Marianne Hupe and Rocio Sedano and Mohammad Shehab and Olga Maria Nardone and Fernando Magro and Ailsa Hart and Sudheer Kumar Vuyyuru},
journal = {Inflammatory Bowel Diseases},
year = {2026},
month = may,
doi = {10.1093/ibd/izag099},
url = {https://doi.org/10.1093/ibd/izag099},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Biologics and small molecules for perianal Crohn’s disease: a systematic review and meta-analyses of randomized placebo-controlled trials
AU - Yuhong Yuan
AU - Vipul Jairath
AU - Jurij Hanzel
AU - Marianne Hupe
AU - Rocio Sedano
AU - Mohammad Shehab
AU - Olga Maria Nardone
AU - Fernando Magro
AU - Ailsa Hart
AU - Sudheer Kumar Vuyyuru
PY - 2026
DA - 2026/05/30
JO - Inflammatory Bowel Diseases
DO - 10.1093/ibd/izag099
UR - https://doi.org/10.1093/ibd/izag099
AB - Background: Although several advanced therapies (ATs) for luminal Crohn’s disease (CD) have been approved, their efficacy for perianal fistulizing Crohn’s (pCD) has not been comprehensively reviewed. Methods: A literature search was conducted in MEDLINE, Embase, and Cochrane CENTRAL up to October 2, 2025. Placebo-controlled randomized controlled trials (RCTs) evaluating treatment efficacy in pCD were included. Outcomes of interest were fistula response and fistula remission during the induction and maintenance trials. Pooled relative risks (RRs) were calculated using a random-effects model. Results: Fourteen studies were eligible; only 4 RCTs were specifically designed for pCD, while the remainder were post hoc analyses of luminal CD studies with moderate to serious risk of bias. In pooled analyses of induction trials (4-28 weeks), ATs were associated with significantly higher induction of fistula response (RR 1.65, 95% CI 1.22-2.22) and remission (RR 1.91, 95% CI 1.37-2.67) compared to placebo. Infliximab and upadacitinib demonstrated significantly greater fistula response and remission, while ustekinumab significantly increased rates of fistula remission. For the maintenance phase (22-52 weeks), ATs were associated with significantly higher maintenance of fistula response (RR 1.54, 95% CI 1.21-1.97) and remission (RR 2.08, 95% CI 1.49-2.90) compared to placebo. Infliximab showed significantly greater maintenance of fistula response and remission compared with placebo, while adalimumab was superior for fistula remission. Conclusion: Findings from our meta-analysis indicate that infliximab is effective for pCD, with limited evidence of benefit with adalimumab, ustekinumab, and upadacitinib. Well-designed RCTs investigating newer advanced therapies are needed to better guide targeted treatment strategies for this patient population.
SN - 1078-0998
SN - 1536-4844
ER -